Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma

• 發表在: Frontiers in Pharmacology
• Main Authors: Jiao Wang, Chengyu Liu, Ronghua Hu, Licheng Wu, Chuanzhou Li
• 格式: Article
• 語言: 英语
• 出版: Frontiers Media S.A. 2024-02-01
• 主題: HCC; immunotherapy; statins; cholesterol; ICI; inflammation
• 在線閱讀: https://www.frontiersin.org/articles/10.3389/fphar.2024.1324140/full

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and accounts for more than 90% of primary liver cancer. The advent of immune checkpoint inhibitor (ICI)-related therapies combined with angiogenesis inhibition has revolutionized the treatment of HCC in late-stage and unresectable HCC, as ICIs alone were disappointing in treating HCC. In addition to the altered immune microenvironment, abnormal lipid metabolism in the liver has been extensively characterized in various types of HCC. Stains are known for their cholesterol-lowering properties and their long history of treating hypercholesterolemia and reducing cardiovascular disease risk. Apart from ICI and other conventional therapies, statins are frequently used by advanced HCC patients with dyslipidemia, which is often marked by the abnormal accumulation of cholesterol and fatty acids in the liver. Supported by a body of preclinical and clinical studies, statins may unexpectedly enhance the efficacy of ICI therapy in HCC patients through the regulation of inflammatory responses and the immune microenvironment. This review discusses the abnormal changes in lipid metabolism in HCC, summarizes the clinical evidence and benefits of stain use in HCC, and prospects the possible mechanistic actions of statins in transforming the immune microenvironment in HCC when combined with immunotherapies. Consequently, the use of statin therapy may emerge as a novel and valuable adjuvant for immunotherapies in HCC.